Transcatheter aortic valve replacement (TAVR) was first performed in 2002.1 Since then, a tremendous amount of progress with this innovative technology has resulted in widespread adoption of this procedure for treatment of aortic valve disease. More than 10 000 TAVRs were performed in the United States alone since Food and Drug Administration (FDA) approval of the first device in 2011.2 Contrary to Europe, where 10 different valves have been approved by the European Union, in the United States all except a few hundred cases have been performed using only 2 valves. These 2 distinctly different transcatheter valve systems have gone through a series of developments. However, the fundamental characteristics of the valves remain unchanged.